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Abstract
Background: Even in the face of a substantial increase in the numbers of endometrial cancer cases and in the
numbers of women who have risk factors, there is no clear agreement about the indications for assessing the
endometria of women with abnormal bleeding or about the tools to use in that assessment. This study sought to
determine in a group of high risk women with abnormal uterine bleeding, the probability that an outpatient
endometrial aspiration would identify significant pathology.
Methods: Retrospective cohort study of the histology from endometrial aspirations performed from 2001 to 2008
for abnormal uterine bleeding at Harbor-UCLA Medical Center and its satellite public health clinics. Medical records
were reviewed in detail to assess risk factors, descriptions of bleeding abnormalities and histologic results.
Results: The charts of 1601 women who underwent 1636 endometrial biopsies for a wide variety of abnormal
uterine bleeding patterns yielded 73 (4.6 %) cases of endometrial carcinoma, 43 cases of atypical endometrial
hyperplasia (2.7 %), for an overall yield of significant pathology of 7.2 %. Hyperplasia without atypia was found in
another 83 cases (5.2 %). Obesity, diabetes and postmenopausal age are associated with an increased risk of
significant pathology. Bleeding patterns were so poorly documented that analysis of yield by this factor should be
viewed with caution.
Conclusions: The probability of detecting significant uterine pathology is greatest among obese, diabetic
postmenopausal women with diabetes (26.3 %). Conversely, the probability of identifying significant pathology in
younger women without risk factors is less than 2 %. For women who perceive their individualized risk estimate to
be too small to justify an endometrial biopsy, it may be possible to offer oral higher dose progestin therapy on the
condition that persistent abnormal bleeding will require more intensive evaluation. These estimates of absolute risk
of being diagnosed with significant pathology on endometrial biopsy may be helpful to patients as they consider
giving informed consent for the procedure.
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Background
Endometrial carcinoma is the most frequent reproduct-
ive cancer in US women; the American Cancer Society
estimates that 54,870 new cases will be diagnosed in
2015 [1]. Despite better understanding of the risk factors
for the most common form of endometrial carcinoma,
endometrial adenocarcinoma and its precursor lesion,
endometrial intraepithelial neoplasia/atypical endomet-
rial hyperplasia, no routine screening tests are currently
available. On the other hand, diagnostic testing has
evolved over the last few decades. Operative curettage
was first replaced by office-based sampling [2–9].
Hysteroscopic evaluation and directed biopsy [10–12],
ultrasonographic assessments [13–18], saline infusion
sonography [12, 19–22], and saline infusion sonography-
directed endometrial biopsy [22] have followed and are
used in different settings to evaluate women with abnor-
mal bleeding for endometrial pathology.
Endometrial evaluation has generally been recom-
mended to evaluate “abnormal uterine bleeding” in at
risk women [23, 24]. ACOG has recommended endo-
metrial sampling for women as young as age 19–39
years who do not respond to medical therapy or who
have prolonged periods of unopposed estrogen stimula-
tion. Risk factors identified included nulliparity, hyper-
tension, body mass index >30, irregular menstruation
and family history [25]. Most recently ACOG has char-
acterized suspicious bleeding as irregular menses, inter-
menstrual bleeding and postmenopausal bleeding and
said that the decision to histologically evaluate abnormal
uterine bleeding in premenopausal women should be
based on symptomatology and clinical presentation [26,
27]. The Canadian Society of Obstetricians and Gynecol-
ogists recommends endometrial sampling in women pre-
senting with abnormal uterine bleeding and age over 40
or weighing more than 90 kg [28]. In all of these cases,
the definitions of “irregular”, “abnormal” and “heavy”
bleeding are not standardized. Although there are mul-
tiple well established risk factors in the development of
endometrial cancer including diabetes, unopposed estro-
gen stimulation and nulliparity [29], rarely are risk
factors other than age and weight considered in the
guidelines.
While much attention has been paid to the relative risks
of developing endometrial cancer and to the sensitivity and
specificity of these various testing modalities, one clinical
question has not received as much attention: If a woman
undergoes endometrial sampling, what is the probability
that significant pathology will be detected to justify such in-
vasive testing in lieu of other options, such as providing
empiric progestin therapy? In the absence of consensus
guidelines regarding when to perform endometrial biopsy,
information regarding yield of such a procedure may assist
providers and patients in making an informed decision.
Harbor-ULCA Medical Center in Torrance, California
has traditionally provided care to indigent, uninsured
women who have limited access to medical services.
Endometrial biopsies have consistently been performed
using Uterine Explora Model 1 (Cooper Surgical, Trum-
bull CT) with 3 mm OD plastic curette with cutting
edges and a 10 cc removable syringe because it has been
thought that such equipment would minimize the fre-
quency of inadequate samples. The purpose of this study
was to determine the probability of finding significant
endometrial pathology (hyperplasia with atypia or endo-
metrial carcinoma) on aspiration of women with differ-
ent risk factors who present with what their clinicians
categorize as “abnormal bleeding”. This information may
guide clinicians in deciding when to recommend endo-
metrial aspiration to individual patients and may provide
patients a basis upon which to decide which to give or
withhold informed consent for the procedure.
Methods
Consent to conduct this research was obtained from the
Research Committee and from the John F. Wolfe Hu-
man Subjects Committee of the Los Angeles BioMedical
Research Institute at Harbor-ULCA Medical Center on
an exempt basis because the study posed no more than
minimal risk and because no personal identifying infor-
mation was collected. Each patient’s chart was consulted
for her age group, medical problems that might contrib-
ute to abnormal bleeding or affect her risk for having
endometrial disease (including her height and weight),
the dimensions of her endometrial specimen, and her
histological results. An attempt was also made to extract
information about the pattern of the woman’s abnormal
bleeding (infrequent, prolonged, and/or heavy, intermen-
strual, postcoital, etc.) to provide additional criteria to
aid in decision-making. Cases were excluded if the endo-
metrial aspiration was not done solely to evaluate bleed-
ing abnormalities, e.g. it was as part of a work-up of
abnormal cervical cytology. Yields are expressed as per-
cent of samples that were found to have significant dis-
ease (endometrial atypia or carcinoma). Atypia was
included in the category of significant disease since it
has been shown to be premalignant and in up to 40 % of
cases, there is an undetected adenocarcinoma [30]. Fish-
ers two-tailed exact test was used to compare frequen-
cies of outcomes; p < 0.05 was used to define statistically
significant differences.
Results
The paper charts and electronic medical records of 1601
women who presented with complaints of abnormal va-
ginal bleeding were reviewed. Important patient charac-
teristics are displayed in Table 1. Perimenopausal
women (age 41–50) constituted 48.3 % of the study
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population. Patient weights ranged from 41 to 219 kg;
BMIs ranged from 17 to 83.9 kg/m2 (mean = 33.02 kg/
m2). Most women (58.0 %) were obese and in 31 % of
the cases, the woman’s weight exceeded 90 kg. Leio-
myoma were reported in 29.8 %. In 14.7 % cases, a his-
tory of diabetes was recorded; 5.3 % had thyroid
dysfunction; 1.9 % provided a history of breast cancer
and 1.1 % volunteered a history of prior endometrial
hyperplasia. Hemoglobin test results were reported in
78.6 % of cases; those hemoglobin levels ranged from 2.1
to 16.4 g/dL and 13.8 % of women had severe anemia
(hemoglobin <8 g/dL). Pulse rates ranged from 40 to
135 beats per minute.
For the study population as a whole, 27 cases of atyp-
ical hyperplasia and 74 cases of uterine (non-cervical)
carcinoma were diagnosed. Table 2 demonstrates the
effect obesity had on the yield of finding significant
pathology. While the incidence of carcinoma did not
differ significantly by BMI (≤30 vs > 30 kg/m2) overall
(4.0 % vs 4.9 %) (p = 0.4); the incidence of atypical
hyperplasia appeared more frequently in obese women
(0.7 % vs 2.4 %) (p = 0.02). The impact of obesity was
greatest in the finding of simple hyperplasia (2.2 % vs
7.3 %) (p < 0.0001).
However, when age is considered a slightly different
picture emerges. Table 3 displays the percent of the
endometrial biopsies found to have atypia or carcinoma
by age and BMI groups. Again it can be seen that these
abnormalities were more frequent in obese women at
every age, but weight’s influence was greatest in the
younger women.
Table 4 displays histological findings reported by age
groups for obese and non-obese diabetic vs. non-
diabetic women. In every age group with sufficient
numbers, women with diabetes had higher rates of sig-
nificant disease (atypia or carcinoma) than those in
whom diabetes had not previously been diagnosed. The
highest yield (22.4 %) was seen in postmenopausal
women with BMI ≥ 30 kg/m2 and diabetes. The preva-
lence of endometritis was consistently higher among
younger women compared to postmenopausal women,
but the frequency of atrophic findings were reversed in
those two groups. Despite the routine use of large plastic
aspirator with a cutting edge, one eighth (12.58 %) of the
specimens were reported to be “inadequate” or “of lim-
ited value”. Rates varied slightly by age, women ≤ 50 years
(11.2 %) versus > 50 years (17.4 %) (p = 0.0017). These
devices were designed to facilitate biopsy in the face of
active bleeding. In this study, 59.7 % of women were re-
ported to have no bleeding; heavy or moderate bleeding
was seen in 17.7 % of patients. Volumes of specimens
varied significantly; in the 1464 cases where three di-
mensions of the specimen were provided by the patholo-
gist, the mean volume was 2.9 mm3, but the standard
deviation was 7.4; the median volume was 1.0 mm3.
Endocervical curettage was performed in conjunction
with the endometrial aspiration in 1397 cases. Cervical
dysplasia was detected in 6 women and cervical carcin-
oma was diagnosed in 29 women, but in 8 cases those
women were found to have adenocarcinoma of the
cervix in conjunction with endometrial carcinoma.
Therefore, only an additional 21 cervical cancers were
detected only by endocervical curettage.
Table 5 displays the categories of bleeding abnormal-
ities that prompted the aspiration (when such data could
be gleaned from for the medical records) by age group
and BMI group. The most common patterns were inter-
mittent, prolonged or excessive bleeding, followed by
postmenopausal bleeding.
Table 6 displays the histological outcomes of the endo-
metrial biopsies done to evaluate women with different
bleeding patterns. Postmenopausal bleeding was associ-
ated with the highest yield of significant disease (atypia
or carcinoma) (16.7 %) and inadequate or limited results
(17.7 %), polyps (10.7 %) and, atrophy (22.7 %). At the
other extreme, women of any age who had normal men-
strual intervals, but prolonged or excessive bleeding had
only a 1.3 % change of significant disease. A single epi-
sode of heavy or prolonged bleeding was associated with
atypia or carcinoma in only 2.4 % of women of all ages.
Table 1 Characteristics of study population by age group












<21 5 33.48 0 75.0 0 0
21–30 88 39.83 15.7 82.0 7.9 9.0
31–40 317 34.49 30.3 58.9 11.1 30.9
41–50 789 31.57 27.1 53.8 12.4 37.2
51–55 232 32.56 24.7 60.0 18.1 27.7
56–55 173 34.25 25.4 60.4 32.0 17.8
>65 31 32.07 16.7 53.3 26.6 −10
Total 1,635 33.03 26.3 58.0 15.0 30.4
aBMI body mass index
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Curiously, the bleeding patterns had little predictive
influence for endocervical samples (Table 7). None of
the women diagnosed with cervical dysplasia or carcinoma
complained of postcoital bleeding. Only “inflammatory
changes” (4.3 %) or “unremarkable endocervical mucosa”
(95.7 %) were reported with postcoital bleeding.
Discussion and Conclusions
The sensitivities and specificities of diagnostic tests have
been compared to a variety of standards, including hys-
terectomy specimens [6, 20, 31–33], operative dilation
and curettage [32, 34, 35], hysteroscopically directed bi-
opsy/curettage [10, 11, 21, 33], and ultrasound-directed
biopsy/curettage [15, 20, 21, 36]. Studies have also evalu-
ated the influence of age [37–40], weight [37–43], dia-
betes [44, 45], and cycle frequency [38, 42, 46] as risk
factors for carcinoma or hyperplasia in both premeno-
pausal and postmenopausal women. Our study sought to
answer a slightly different clinical question: What is the
likelihood that a woman who presents with a bleeding
abnormality with a given BMI and age would have a sig-
nificant disease (endometrial intraepithelial neoplasia
atypical hyperplasia or carcinoma) detected by one
endometrial aspiration?
The women in our study had among the highest
prevalence or of endometrial cancer reported to date,
which allows us to provide a more secure estimate of
the upper limit of the potential for disease detected by
endometrial aspiration [46]. None of the women in this
study was using unopposed estrogen therapy. However,
the majority had BMI >30 kg/m2. Obesity is a well-
recognized as a risk factor for endometrial cancer with a
200–400 % linear increase in risk with each point in-
crease in BMI [47], but there is some controversy about
whether obesity is more impactful among premeno-
pausal women [35] or among postmenopausal women
[40]. We found that BMI increased the risk of atypia in
every age group, but carcinoma detection rates were
similar in obese and non-obese women. Postcoital bleed-
ing was not associated with cervical dysplasia or carcin-
oma, but given the small number of women with that
complaint, this finding may not contradict the finding of
Rosenthal et al. that invasive cancer is rare in women
with postcoital bleeding, but more common than in the
general population [48].
The premenopausal women in our study had higher
risk features than earlier studies and higher rates of
detection of endometrial hyperplasia (with or without
atypia) and endometrial cancer, (8.8 %). Previous Investi-
gators have reported rates of combined hyperplasia and
cancer on endometrial biopsy of women presenting with
abnormal bleeding ranging from 5 to 7.7 % [37, 38]. The
fact that our estimate of risk for all forms of pathology
exceed previously reported finding supports their value
as upper limits of risk.
The impact that age has on the prevalence of significant
pathology had been reported in a large study of pathology
reports. Again women of that age group in our study had
proportionately more cases of pathology. Because we had
more information about the women than earlier investiga-
tors, we were able to isolate the impacts of weight as well
as known diabetes might have on the probability that sig-
nificant pathology would be identified on biopsy [49].
Table 2 Yield of endometrial aspiration: impact of obesity
Pathology result Total population BMI≤ 30* BMI >30*
Number % % %
Inadequate/limited 206 12.6 14.1 11.5
Endometritis 172 10.5 12.3 9.5
Proliferative/disordered proliferation 444 27.2 26.9 27.6
Secretory/decidualized/menstrual 351 21.5 24.4 20.6
Atrophy 97 5.9 6.7 4.8
Polyp 158 9.7 8.1 10.6
Simple hyperplasia 89 5.4 2.2 7.3
Complex hyperplasia 16 1.0 0.6 1.3
Hyperplasia with atypia 27 1.6 0.7 2.7
Endometrial carcinoma 74 4.5 4.1 4.9
Total 1635 99.9 100.1 100.4
* BMI body mass index in Kg/m2
Table 3 Percent of biopsies demonstrating hyperplasia with
atypia or carcinoma by age and BMI groups
BMI Age (years)
<40 41–51 >50 All
≤30 2.1 % 1.9 % 12.9 % 4.8 %
>30 5.9 % 4.0 % 14.1 % 7.3 %
BMI body mass index in Kg/m2
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Polyps were diagnosed on pathology in 12.1 % of our
subjects overall. Malignancy confined to the polyp was
reported in only one case, which is much lower than the
4.2 % rate of malignancy or atypia found within polyps
reported earlier in symptomatic postmenopausal women
[50]. Because we specifically excluded women who had
abnormal cervical cytology, we cannot comment on the
utility of HPV testing to distinguish between cervical
and endometrial cancer in women with atypical glandu-
lar changes as recommended by Castle et al. [51].
In patients with abnormal bleeding related to obesity,
thyroid dysfunction, etc., a short course of hormonal
therapy for abnormal of bleeding will not be curative as
it would not treat the underlying condition [52]. How-
ever, prolonged therapy with progestin will prevent de-
velopment of endometrial hyperplasia and control
bleeding excesses until the underlying cause is addressed
[53]. Progestin containing OCPs and progestin-releasing
IUDs are effective in treating endometrial hyperplasia
via progestin-meditated reversal of the PTEN suppressor
genes [54, 55]. The relatively low rates of significant
pathology found in our study among the younger
women with normal risk factors and perimenopausal
women with single episodes of heavy bleeding may make
those women hesitate to agree to biopsy, but to be more
accepting of a therapeutic trial of progestin therapy with
the understanding that persistent abnormal bleeding
would change these estimates and indicate a stronger
need for biopsy. The information provided by this analu-
sis may also be helpful in calculating the cost effective-
ness of screening women with different clinical
presentations [40, 56].
Torres et al. reported that one fourth of patients diag-
nosed with endometrial cancer had previous benign
endometrial sample results [57]. Close follow-up is
essential as are measures to prevent recurrent abnormal
bleeding or development of hyperplasia, but these ser-
vices often not implemented [53, 58–65]. Over 1 % of
Table 4 Histology by age, BMI and diabetes status (%)
Age <40 years Age 41–50 years Age > 50 years
BMI <30 BMI ≥30 BMI <30 BMI ≥30 BMI <30 BMI ≥30
No DM DM No DM DM No DM DM No DM DM No DM DM No DM DM
Number of subjects 132 11 226 30 334 23 347 73 146 24 179 76
Inadequate/limited 12.9 27.3 10.2 10.0 12.6 8.7 8.9 11.1 15.8 29.2 16.2 17.1
Endometritis 12.9 18.2 10.2 6.7 14.4 13.0 12.7 11.1 6.8 8.3 3.9 5.3
Proliferative/disordered 28.0 36.4 29.6 13.3 30.5 26.1 32.3 24.7 18.5 16.7 27.4 9.2
Secretory/decidualized/menstrual 29.5 18.2 24.3 10.0 29.0 39.1 26.2 24.7 11.0 – 6.1 7.9
Atrophy 0 0 0 0 0.8 4.3 1.4 2.7 23.3 29.2 16.8 14.5
Polyp 12.1 0 8.8 23.3 7.2 8.7 12.2 8.2 8.2 – 11.2 7.9
Simple hyperplasia 2.3 0 11.1 16.7 2.7 3.7 5.5 2.1 – 7.8 9.2
Complex hyperplasia 0 0 0.9 6.7 0.3 0 4.1 2.1 – 1.7 2.6
Hyperplasia with atypia 0.8 0 2.2 6.7 0.8 2.3 4.1 0.7 – 0.6 3.9
Endometrial carcinoma 1.5 0 2.7 6.7 1.2 0.9 4.1 11.6 16.7 8.4 22.4
BMI body mass index in Kg/m2, DM diabetes melitis
Table 5 Bleeding or ultrasound abnormalities which prompted biopsy (number specimens)
Bleeding or ultrasound abnormality Age≤ 40 years Age 41–50 years Age ≥50 years Total
BMI <30 BMI ≥30 BMI ≤30 BMI >30 BMI ≤30 BMI >30
Infrequent bleeding 20 85 50 23 6 15 199
Prolonged or excessive multiple episodes 75 110 232 212 24 44 697
Single episode 31 55 71 68 10 9 244
Intermenstrual 18 21 40 37 13 7 136
Postmenopausal 1 1 28 16 108 170 324
Post-coital 4 6 5 6 3 1 24
Thickened endometrium (ultrasound) 3 2 4 4 10 12 35
Unclassified – – 1 1 – 5
Total 142 255 415 356 170 255 1593
BMI body mass in Kg/m2
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patients in our study presented with a history of prior
endometrial hyperplasia, but none was on any suppres-
sive therapy. This is not an isolated problem, in one
series of women treated for hemoglobin ≤5 mg/dL, due
to excessive vaginal bleeding, over 25 % had been previ-
ously transfused, but none of these women was on any
medical therapy to control future menstrual losses [66].
Despite the large number of cases studied and the high
prevalence of disease found in our study, our results are
not precise. However, they can provide estimates of the
upper limit of finding significant pathology with
endometrial biopsy. We have analyzed the data in vari-
ous combinations of risk factors to provide the most in-
formation about the absolute risk, not relative risk. We
offer our data to others with interest in this area in
hopes that it may be combined with data from other in-
vestigators to refine the estimates of the yield of endo-
metrial sampling in different clinical settings [67].
However, we recognize that these data are not applicable
for one of the most common clinical scenarios—bleeding
in women using postmenopausal hormone therapy—since
none of our subjects reported current use of those agents.














12.8 12.0 6.2 13.6 17.0 4.2 23.3 0








20.3 27.3 32.8 22.9 3.3 8.3 10.0 0
Atrophy 1.1 0.9 – 2.1 22.7 4.2 26.7 0
Polyploid 11.2 8.3 11.2 10.7 10.7 12.5 6.7 0
Simple
hyperplasia
8.0 4.5 6.2 4.3 6.0 4.2 6.7 0
Complex
hyperplasia
1.6 0.6 0.8 0.7 1.2 0 6.7 0
Atypia 2.7 1.0 1.2 2.9 2.4 8.3 0 0
Endometrial
carcinoma
3.2 1.0 0.8 7.9 14.3 0 0 0
Total 99.9 100.1 99.8 100.1 100.0 100.1 100.1 100.0


















88.1 86.6 84.2 82.5 85.4 91.3 71.4 0
Inflammation/
infection
3.8 6.4 7.7 8.3 6.1 4.3 23.8 0
Polyp 0.6 1.5 1.4 0.8 0.7 0 0 0
Dysplasia 0.6 0.9 0.5 1.7 1.1 0 0 0
Cervical cancer:
squamous
0 0.2 0 – 1.8 0 0 0
Cervical cancer:
endocervical
1.3 0.3 1.0 0.8 1.8 0 0 0
Total ECC 100.0 100.0 100.1 99.9 100.1 100.1 100.0 100.0
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As a retrospective study, we are not able to characterize
the bleeding patterns with as much accuracy as would be
possible in a prospective trial [68]. Accurate categorization
into bleeding groups was challenging given the paucity of
menstrual data recorded in some of the records. However,
at a minimum, it is hoped that our detailed analysis by age
group, BMI and presenting bleeding pattern may help
provide more individually relevant information for the
clinician and the patient to utilize when making diagnostic
decisions.
Condensation
The probability of finding significant uterine pathology
on endometrial aspiration varies greatly by patient risk
factors and clinical presentation, but is generally less
than 2 % in premenopausal women with BMI <30 kg/m2
and without diabetes who complain of abnormal bleeding.
The highest yield (22.4 %) was in postmenopausal women
with diabetes and BMI ≥30 kg/m2.
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